KRAS4b-PDEδ stablizer C19 is a small molecule that binds and stablizes the KRAS4b-PDEδ complex, decreases the viability and proliferation of colorectal cancer cells.

K-Ras(G12C) inhibitor 6 is an allosteric, and selective inhibitor of oncogenic K-Ras(G12C).

KRAS inhibitor Cmpd2 is a small-molecule compound that blocks biochemical and cellular functions of KRASG12V with IC50 of 0.8 uM in vitro.

KRAS inhibitor C6ME is a small-molecule compound that blocks biochemical and cellular functions of KRASG12V in vitro..

KRAS inhibitor 11 is a first-in-class, high-affinity, noncovalent allosteric KRAS inhibitor, disrupts KRAS-Raf interaction with Kd of 1.2 uM.

KRAS G12C inhibitor 11 is a potent, selective, covalent and irreversible inhibitor of KRAS G12C, inhibits KRAS dependent ERK-phosphorylation in the H358 cell with IC50 of 5 nM.

KR-62436 (KR62436) is a potent, selective DPP4 inhibitor with IC50 of 0.78, 0.49, 0.14 uM for rat plasma, porcine kidney, human DPP4 (Caco-2), respectively.

KR-33028 is a potent, highly selective NHE1 inhibitor with IC50 of 2.59 uM.

KR-32570 is a potent sodium hydrogen exchanger NHE1 inhibitor with IC50 of 50 nM.

KPT-185 is an orally bioavailable selective inhibitor of CRM1 amd displayes potent antiproliferative properties at submicromolar concentrations,induced apoptosis (average 5-fold increase), cell-cycle arrest, and myeloid differentiation in AML cell lines a

KP372-1 is a specific Akt inhibitor that blocks proliferation and induces apoptosis of thyroid cancer cells with an IC50 value of 30-60 nM in vitro.

KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials.

KJ-Pyr-9 is a novel small-molecule inhibitor of c-Myc (Kd=6.5 ± 1.0 nM).

KIRA-7 is a small molecule inhibitor of IRE1α kinase/Rnase with IC50 of 0.11/0.22 uM, allosterically inhibits IRE1α RNase activity.

Kinetin (6-Furfuryladenine)

Kinesore is an inhibitor of the KLC2-SKIP Interaction.

KIN-281 is a small molecule that inhibits multiple kinases including MELK and the non-receptor tyrosine kinase BMX with IC50 of 1.4 and 1.9 uM, respectively.

Kif15-IN-1 is a potent, selective inhibitor of KIF15 motility, can act synergistically with Eg5 inhibitors to impair cancer cell proliferation..

KI16 is a novel small molecules that inhibit STAT3-dependent transcription and function, interacts with the STAT3 SH2 domain.

KHK-IN-8 is a potent ketohexokinase (KHK) inhibitor with IC50 of 12 nM, interacts with Asp-27B in the ATP-binding region of KHK, also shows potent cellular KHK inhibition with IC50 of <500 nM..

KHK-IN-8 is a potent ketohexokinase (KHK) inhibitor with IC50 of 12 nM, interacts with Asp-27B in the ATP-binding region of KHK, also shows potent cellular KHK inhibition with IC50 of <500 nM..

KH-CB19 is a potent and highly specific inhibitor of CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4) with IC50 of 20 nM (CLK1), displays almost 100-fold selectivity against the CLK3 isoform.

KH176 is a chemical entity derivative of Trolox and small molecule ROS-redox modulator, shows potential treatment for mitochondrial disorders.

KH-176 (KH176, Sonlicromanol) is a smal molecule ROS-redox modulator, effectively reduces increased cellular ROS levels and protects OXPHOS deficient primary cells against redox perturbation by targeting the Thioredoxin/Peroxiredoxin system.

KGP-94 is a potent, selective cathepsin L inhibitor with IC50 of 189 nM, shows no significant inhibitory effect on cathepsin B (IC50>10 uM).

KGP-420 is the water-soluble phosphate prodrug of KGP-94 in vivo studies, KGP-94 is a potent, selective cathepsin L inhibitor with IC50 of 189 nM.

KG-548 is an ARNT/TACC3 disruptor (IC50=25 uM) that selectively bind within the ARNT PAS (Per-ARNT-Sim) domain that recruits TACC3..

Ketotifen (fumarate) is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer, which is used to prevent asthma attacks.

Ketorolac (Ketorolac tromethamine, Toradol) is a non-selective COX inhibitor with strong analgesic activity.

Ketoprofen (Actron) is a non-selective NSAID with IC50 of 0.5 μM and 2.33 μM for human recombinant COX-1 and COX-2, respectively.